2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
7
Prostatic Neoplasms
2
Neoplasms
2
Lung Neoplasms
2
Urinary Bladder Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Peripheral Nervous System Diseases
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Nasopharyngeal Carcinoma
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Acute
1
Gastroesophageal Adenocarcinoma
1
Depression
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma
1
Anxiety Disorders
1
Interventions
pembrolizumab
92
Gemcitabine
56
Nivolumab
50
Cisplatin
39
atezolizumab
37
Carboplatin
30
avelumab
29
enfortumab vedotin
26
Docetaxel
23
Magnetic Resonance Spectroscopy
19
Mitomycin
17
Ipilimumab
17
Paclitaxel
16
Specimen Handling
14
durvalumab
11
toripalimab
10
sacituzumab govitecan
10
Pemetrexed
10
cabozantinib
9
Taxes
8
vinflunine
7
Cyclophosphamide
7
tislelizumab
6
Injections
6
Bevacizumab
6
pemigatinib
5
fludarabine
5
disitamab vedotin
5
Standard of Care
5
Radiosurgery
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
Single Person
×
Clear all
NCT07629700
2026-06-05
ENDEAVOR
University of Florence
Phase NA
Not yet recruiting
40 enrolled